GlassScriptPhysician profile
Alice Gordon
NPI 1811222045
$2,895.45
in general payments reported to CMS, 2019-2025
30 companies · $2,108 in 2025
The $2,108 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $64.38 · 2022: $94.18 · 2023: $129 · 2024: $500 · 2025: $2,108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,736.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $637.30 | 2021-2025 | Erleada, Rybrevant, Carvykti |
| Merck Sharp & Dohme LLC | $345.92 | 2024-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Novartis Pharmaceuticals Corporation | $246.54 | 2025 | |
| Tersera Therapeutics LLC | $159.13 | 2024-2025 | Zoladex |
| Regeneron Healthcare Solutions, INC. | $127.90 | 2025 | Libtayo |
| Alexion Pharmaceuticals, INC. | $120.06 | 2024-2025 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $119.22 | 2024-2025 | |
| Pfizer INC. | $118.15 | 2025 | |
| Genentech USA, INC. | $103.90 | 2024-2025 | Tecentriq, Tecentriq Hybreza, Venclexta |
| Adaptive Biotechnologies Corporation | $97.16 | 2023-2025 | Clonoseq |
| Stemline Therapeutics INC. | $90.93 | 2025 | Orserdu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.35 | 2024-2025 | |
| Glaxosmithkline, LLC. | $79.06 | 2024-2025 | Jemperli, Zejula |
| Puma Biotechnology, INC. | $69.72 | 2024-2025 | |
| Pharmaessentia USA Corporation | $57.80 | 2024-2025 | Besremi |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $52.47 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.42 | 2025 | Ninlaro |
| Lilly USA, LLC | $49.29 | 2024-2025 | Verzenio, Jaypirca |
| Taiho Oncology, INC. | $27.41 | 2025 | |
| Novocure INC. | $26.17 | 2025 | Optune Lua (Novottf-200t) |
| Adc Therapeutics America, INC. | $25.07 | 2024 | |
| Daiichi Sankyo INC. | $24.90 | 2025 | Datroway |
| Abbott Laboratories | $23.94 | 2024 | Freestyle Libre 3 |
| Recordati_rare_diseases_inc. | $23.41 | 2025 | Sylvant |
| Abbvie INC. | $23.32 | 2024 | |
| Kyowa Kirin, INC. | $22.41 | 2024 | Poteligeo |
| Astellas Pharma US INC | $22.12 | 2025 | Padcev |
| Emd Serono, INC. | $21.82 | 2025 | |
| Apellis Pharmaceuticals, INC. | $21.81 | 2025 | |
| Gilead Sciences, INC. | $19.75 | 2024 | Trodelvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alice Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.